Genmab — Maj 2019
-
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). http://abstracts.asco.org/239/AbstView_239_247207.html
-
Bryan Garnier
"Isatuximab is not better than DarzalexDetailed results of ICARIA-MM study to be presented at ASCO
Good results but not better than with Darzalex
Darzalex will benefit from the subcutaneous administration
We reduce our forecasts for isatuximab" -
the JNJ ASCO press release also mentions the Investigational Bispecific JNJ-61186372 (and offcourse Dara ) https://www.jnj.com/janssen-to-present-data-from-robust-oncology-portfolio-and-pipeline-at-the-2019-asco-annual-meeting-including-best-of-asco-selections
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind